Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Journal: Nature medicine
Published: December 20, 2021
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Journal: Journal for immunotherapy of cancer
Published: December 04, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Journal: The Lancet. Oncology
Published: June 25, 2020
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.
Journal: Journal for immunotherapy of cancer
Published: April 11, 2019
Reviewing the role of healthy volunteer studies in drug development.
Journal: Journal of translational medicine
Published: November 24, 2018
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
Journal: Investigational new drugs
Published: October 08, 2018
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Journal: PloS one
Published: April 20, 2017
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Journal: The Lancet. Oncology
Published: October 14, 2015
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
Journal: BJU international
Published: February 20, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026